Skip to main content

Lumbosacral Radiculopathy

2
Pipeline Programs
5
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Lotus Pharmaceuticals
Lotus PharmaceuticalsTaiwan - Taipei
1 program
1
Clonidine MicropelletsPhase 31 trial
Active Trials
NCT03727100Completed207Est. Jul 2020
AfaSci
AfaSciCA - Redwood City
1 program
1
AFA-281Phase 21 trial
Active Trials
NCT06649747Not Yet Recruiting408Est. Mar 2032
Kolon Life Science
Kolon Life ScienceKorea - Seoul
1 program
KLS-2031N/A1 trial
Active Trials
NCT05613569Active Not Recruiting5Est. Apr 2027
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Move-MOREN/A1 trial
Active Trials
NCT07125027Recruiting32Est. Nov 2026
Biogen
BiogenCAMBRIDGE, MA
1 program
CNV1014802PHASE_21 trial
Active Trials
NCT01561027Completed82Est. Aug 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Lotus PharmaceuticalsClonidine Micropellets
AfaSciAFA-281
BiogenCNV1014802
Oregon TherapeuticsMove-MORE
Kolon Life ScienceKLS-2031

Clinical Trials (5)

Total enrollment: 734 patients across 5 trials

NCT03727100Lotus PharmaceuticalsClonidine Micropellets

Treatment of Pain Associated With Lumbosacral Radiculopathy in Adults

Start: Oct 2018Est. completion: Jul 2020207 patients
Phase 3Completed
NCT06649747AfaSciAFA-281

Safety and Efficacy Study on AFA-281 for the Treatment of Low Back Pain

Start: Apr 2027Est. completion: Mar 2032408 patients
Phase 2Not Yet Recruiting
NCT01561027BiogenCNV1014802

Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Start: Apr 2011Est. completion: Aug 201282 patients
Phase 2Completed
NCT07125027Oregon TherapeuticsMove-MORE

A Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE

Start: Aug 2025Est. completion: Nov 202632 patients
N/ARecruiting
NCT05613569Kolon Life ScienceKLS-2031

A Long-term, 3-Year, Follow-up Study for Patients Completing the KS-GIG-001-01 Study

Start: Jul 2022Est. completion: Apr 20275 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 734 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.